Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | ECE1 | P42892 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042933 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNACA14CA12ECE1 | |
| SCHEMBL27210229 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2CA14CA12MMECA7 | |
| SCHEMBL1176824 | 0.78 | TDP1 (0.44) | SMN1; SMN2CA14CA12ECE1MME | |
| SCHEMBL9212731 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12MAPTCA7 | |
| SCHEMBL5513850 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12MAPTCA7 | |
| SCHEMBL1176819 | 0.78 | TDP1 (0.44) | SMN1; SMN2CA14CA12ECE1MME | |
| SCHEMBL17000160 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12MAPTCA7 | |
| SCHEMBL1177115 | 0.78 | TDP1 (0.44) | SMN1; SMN2CA14CA12ECE1MME | |
| SCHEMBL24696823 | 0.78 | SLC1A3 (0.43) | LMNAECE1MAPTMCL1 | |
| SCHEMBL3042873 | 0.78 | SLC1A3 (0.43) | LMNAECE1MAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2066688-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | SMN1; SMN2 877/4885LMNA 1174/4885CA14 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.